Looking for the right gateway drug to help start up an insatiable medical literature habit? 

JournalJunkies, your ears are in the right place!

Today we interview Dr James Galloway, rheumatologist, semi- ornithologist, clinical lecturer, and head of the TACTIC trial at King's Hospital.
He helps guide us through the mysteries of immunomodulation in COVID in understandable terms. What do the trials show us? Why? And, what is on the COVID horizon?

02:00    Introductions
02:45    Why the birds aren't coming to your garden
04:45    The Recovery Trial
08:00   Why Steroids?
09:35    REMAP CAP
13:45    The conflicting Tocilizumab data
17: 40    What is Tocilizumab and why might it work?
24:50     The value of CRP monitoring
27:00      Who to give Tocilizumab to
29:40     TACTIC trial
34:30     Why study SGLT2 inhibitors
37:00     The future Tx of Severe COVID
40:00     The JournalSpotting Gateway drug

Support the show

Visit the website on www.journalspotting.com.
Follow us on Twitter @JournalSpotting.
Email us on [email protected].
Get our JournalClub App on https://journalclub.messly.com
Share us with all your colleagues!